Junqiang Dai, Ph.D.

Professional Background

Dr. Junqiang Dai is a Research Assistant Professor in the Department of Biostatistics and Data Science at the University of Kansas Medical Center, where he completed his PhD in Biostatistics. Before becoming a faculty member, he served as a Senior Research Analyst/Statistician II, gaining substantial expertise in statistical analysis and research methodology. His role involves collaborative research across diverse medical fields, alongside teaching and conducting methodological research. His primary research interests focus on early-phase clinical trial design and adaptive clinical trial design with time-to-event endpoints.

• PhD, Biostatistics, University of Kansas Medical Center, Kansas City, Kansas
• MS, Biostatistics, University of Kansas Medical Center, Kansas City, Kansas
• BS, Life Science and Biotechnology, Wuhan University, Wuhan, Hubei

• Dai, Junqinag, He, Jianghua, Phadnis, Milind., A. 2024. Sample size considerations for single-arm clinical trials with time-to-event endpoint using the gamma distribution. Contemporary Clinical Trials Communications, 101344
• Rasu, Rafia., S, Phadnis, Milind., A, Xavier, Christy, Dai, Junqiang, Hunt, Suzanne., L, Jain, Nishank. 2024. P2Y12 Inhibitors Refill Gap Predicts Death in Medicare Beneficiaries on Chronic Dialysis. Kidney International Reports
• Saeed, Anwaar, Park, Robin, Pathak, Harsh, Al-Bzour, Ayah., Nedal, Dai, Junqiang, Phadnis, Milind, Al-Rajabi, Raed, Kasi, Anup, Baranda, Joaquina, Sun, Weijing, others. 2024. Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort. Nature Communications, 15 (1), 1533
• Sun, Weijing, Veeramachaneni, Nirmal, Al-Rajabi, Raed, Madan, Rashna, Kasi, Anup, Al-Kasspooles, Mazin, Baranda, Joaquina, Saeed, Anwaar, Phadnis, Milind., A, Godwin, Andrew., K, others. 2023. A phase II study of perioperative pembrolizumab plus mFOLFOX in patients with potentially resectable esophagus, gastroesophageal junction (GEJ), and stomach adenocarcinoma.. Cancer Medicine
• Saeed, Anwaar, Park, Robin, Dai, Junqiang, Al-Rajabi, Raed, Kasi, Anup, Baranda, Joaquina, Williamson, Stephen, Saeed, Azhar, Ripp, Jacob, Collins, Zachary, others. 2023. Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: Phase Ib CAMILLA trial results. Cell Reports Medicine
• Jain, Nishank, Corken, Adam, Arthur, John., M, Ware, Jerry, Arulprakash, Narenraj, Dai, Junqiang, Phadnis, Milind., A, Davis, Otis, Rahmatallah, Yasir, Mehta, JL, others. 2023. Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease. Vascular Pharmacology, 107143